Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

RH Jones; K Fizazi; ND James; TL Tammela; N Matsubara; F Priou; P Beuzeboc; T Lesimple; P Bono; V Kataja; JA Garcia; A Protheroe; N Shore; J Aspegren; H Joensuu; I Kuss; S Fiala-Buskies; E Vjaters

doi:10.1038/s41391-023-00740-9

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

RH Jones (Corresponding Author), K Fizazi, ND James, TL Tammela, N Matsubara, F Priou, P Beuzeboc, T Lesimple, P Bono, V Kataja, JA Garcia, A Protheroe, N Shore, J Aspegren, H Joensuu, I Kuss, S Fiala-Buskies, E Vjaters

Research output: Contribution to journal › Article › peer-review

Original language	English
Number of pages	4
Journal	Prostate Cancer and Prostatic Diseases
DOIs	https://doi.org/10.1038/s41391-023-00740-9
Publication status	E-pub ahead of print - 26 Oct 2023
Externally published	Yes

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

1.1. Scientific article indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41391-023-00740-9

Cite this

Jones, RH., Fizazi, K., James, ND., Tammela, TL., Matsubara, N., Priou, F., Beuzeboc, P., Lesimple, T., Bono, P., Kataja, V., Garcia, JA., Protheroe, A., Shore, N., Aspegren, J., Joensuu, H., Kuss, I., Fiala-Buskies, S., & Vjaters, E. (2023). Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. Advance online publication. https://doi.org/10.1038/s41391-023-00740-9

@article{15ac9c380e98433493b3adf1dffa9525,

title = "Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer",

author = "RH Jones and K Fizazi and ND James and TL Tammela and N Matsubara and F Priou and P Beuzeboc and T Lesimple and P Bono and V Kataja and JA Garcia and A Protheroe and N Shore and J Aspegren and H Joensuu and I Kuss and S Fiala-Buskies and E Vjaters",

year = "2023",

month = oct,

day = "26",

doi = "10.1038/s41391-023-00740-9",

language = "English",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Springer Nature",

}

Jones, RH, Fizazi, K, James, ND, Tammela, TL, Matsubara, N, Priou, F, Beuzeboc, P, Lesimple, T, Bono, P, Kataja, V, Garcia, JA, Protheroe, A, Shore, N, Aspegren, J, Joensuu, H, Kuss, I, Fiala-Buskies, S & Vjaters, E 2023, 'Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer', Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-023-00740-9

TY - JOUR

T1 - Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

AU - Jones, RH

AU - Fizazi, K

AU - James, ND

AU - Tammela, TL

AU - Matsubara, N

AU - Priou, F

AU - Beuzeboc, P

AU - Lesimple, T

AU - Bono, P

AU - Kataja, V

AU - Garcia, JA

AU - Protheroe, A

AU - Shore, N

AU - Aspegren, J

AU - Joensuu, H

AU - Kuss, I

AU - Fiala-Buskies, S

AU - Vjaters, E

PY - 2023/10/26

Y1 - 2023/10/26

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:001096093100001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1038/s41391-023-00740-9

DO - 10.1038/s41391-023-00740-9

M3 - Article

C2 - 37884613

SN - 1365-7852

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

ER -

Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this